Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 2
1999 2
2000 3
2001 5
2002 6
2003 4
2004 2
2005 10
2006 10
2007 11
2008 12
2009 13
2010 13
2011 7
2012 12
2013 11
2014 11
2015 17
2016 21
2017 31
2018 18
2019 17
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

210 results
Results by year
Filters applied: . Clear all
Page 1
NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E, Scaltriti M, Drilon A. Cocco E, et al. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. doi: 10.1038/s41571-018-0113-0. Nat Rev Clin Oncol. 2018. PMID: 30333516 Free PMC article. Review.
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Drilon A, et al. Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9. Cancer Discov. 2017. PMID: 28183697 Free PMC article. Clinical Trial.
Targeting TRK family proteins in cancer.
Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Khotskaya YB, et al. Pharmacol Ther. 2017 May;173:58-66. doi: 10.1016/j.pharmthera.2017.02.006. Epub 2017 Feb 4. Pharmacol Ther. 2017. PMID: 28174090 Review.
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez L. Rolfo C, et al. Expert Opin Investig Drugs. 2015;24(11):1493-500. doi: 10.1517/13543784.2015.1096344. Epub 2015 Oct 12. Expert Opin Investig Drugs. 2015. PMID: 26457764 Review.
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Drilon A, Nagasubramanian R, Blake JF, Ku N, Tuch BB, Ebata K, Smith S, Lauriault V, Kolakowski GR, Brandhuber BJ, Larsen PD, Bouhana KS, Winski SL, Hamor R, Wu WI, Parker A, Morales TH, Sullivan FX, DeWolf WE, Wollenberg LA, Gordon PR, Douglas-Lindsay DN, Scaltriti M, Benayed R, Raj S, Hanusch B, Schram AM, Jonsson P, Berger MF, Hechtman JF, Taylor BS, Andrews S, Rothenberg SM, Hyman DM. Drilon A, et al. Cancer Discov. 2017 Sep;7(9):963-972. doi: 10.1158/2159-8290.CD-17-0507. Epub 2017 Jun 3. Cancer Discov. 2017. PMID: 28578312 Free PMC article. Clinical Trial.
Indole-like Trk receptor antagonists.
Tammiku-Taul J, Park R, Jaanson K, Luberg K, Dobchev DA, Kananovich D, Noole A, Mandel M, Kaasik A, Lopp M, Timmusk T, Karelson M. Tammiku-Taul J, et al. Eur J Med Chem. 2016 Oct 4;121:541-552. doi: 10.1016/j.ejmech.2016.06.003. Epub 2016 Jun 4. Eur J Med Chem. 2016. PMID: 27318978
Role of TrkA signalling and mast cells in the initiation of osteoarthritis pain in the monoiodoacetate model.
Sousa-Valente J, Calvo L, Vacca V, Simeoli R, Arévalo JC, Malcangio M. Sousa-Valente J, et al. Osteoarthritis Cartilage. 2018 Jan;26(1):84-94. doi: 10.1016/j.joca.2017.08.006. Epub 2017 Aug 24. Osteoarthritis Cartilage. 2018. PMID: 28844566 Free article.
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS. Laetsch TW, et al. Lancet Oncol. 2018 May;19(5):705-714. doi: 10.1016/S1470-2045(18)30119-0. Epub 2018 Mar 29. Lancet Oncol. 2018. PMID: 29606586 Free PMC article. Clinical Trial.
Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.
Bailey JJ, Schirrmacher R, Farrell K, Bernard-Gauthier V. Bailey JJ, et al. Expert Opin Ther Pat. 2017 Jul;27(7):831-849. doi: 10.1080/13543776.2017.1297797. Epub 2017 Mar 8. Expert Opin Ther Pat. 2017. PMID: 28270021 Review.
210 results
Jump to page
Feedback